**Mozambique**

Population 2017: 30 million

### Tuberculosis profile

#### Mortality (excludes HIV+TB)

- Number (thousands): 22 (13–33)
- Rate (per 100,000 population): 73 (43–111)

#### Mortality (HIV+TB only)

- Number (thousands): 27 (17–39)
- Rate (per 100,000 population): 90 (56–131)

#### Incidence (includes HIV+TB)

- Number (thousands): 163 (106–233)
- Rate (per 100,000 population): 551 (356–787)

#### Incidence (HIV+TB only)

- Number (thousands): 66 (42–95)
- Rate (per 100,000 population): 221 (141–319)

#### Incidence (MDR/RR-TB)**

- Number (thousands): 8.8 (4.6–14)
- Rate (per 100,000 population): 30 (15–48)

#### Estimated TB incidence by age and sex (thousands)*

<table>
<thead>
<tr>
<th>Age Group</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Females</td>
<td>11 (9.6–12)</td>
</tr>
<tr>
<td>Males</td>
<td>12 (11–13)</td>
</tr>
<tr>
<td>Total</td>
<td>23 (19–26)</td>
</tr>
</tbody>
</table>

#### TB case notifications, 2017

- Total cases notified: 86,515
- Total new and relapse: 85,376
- % tested with rapid diagnostics at time of diagnosis: 96%
- % with known HIV status: 93%
- % bacteriologically confirmed among pulmonary: 40%

#### Universal health coverage and social protection

- TB treatment coverage (notified/estimated incidence), 2017: 52% (37–81)
- TB patients facing catastrophic total costs: 0.31 (0.17–0.46)

#### Universal health coverage and social protection

- TB/HIV care in new and relapse TB patients, 2017
  - Number (%): 33,514 (40%)
  - on antiretroviral therapy: 31,790 (95%)

#### Drug-resistant TB care, 2017

- New cases: Estimated MDR/RR-TB cases among notified pulmonary TB cases: 4,100
- Previously treated cases: 2,500–5,700
- Total number**: 4,100

#### Treatment success rate and cohort size

- New and relapse cases registered in 2016: 90% (70,510)
- Previously treated cases, excluding relapse, registered in 2016: 86% (1,593)
- HIV-positive TB cases registered in 2016: 87% (30,572)
- MDR/RR-TB cases started on second-line treatment in 2015: 48% (646)
- XDR-TB cases started on second-line treatment in 2015: 38% (16)

#### TB preventive treatment, 2017

- % of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment: >100%

#### TB financing, 2018

- National TB budget (US$ millions): 30

Funding source: 5% domestic, 95% international, 0% unfunded

---

* Ranges represent uncertainty intervals

** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin

*** Includes cases with unknown previous TB treatment history

**** Includes patients diagnosed before 2017 and patients who were not laboratory-confirmed

---

Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.

Generated: 2019-01-10

Data: www.who.int/tb/data